基线疾病严重程度对阿普司特治疗达标的影响:汇总分析
该汇总分析纳入四项临床试验中接受阿普司特30mg每日两次治疗的中重度斑块状银屑病患者,按基线PASI四分位分组,评估第32周PASI≤2达标率。结果显示基线PASI较低者达标率更高(Q1 43.5% vs Q4 18.4%),且多数达标患者同时达到DLQI≤5。
要点
- 基线PASI较低的患者第32周PASI≤2达标率更高。
- 达到PASI≤2的患者中83.6%同时达到DLQI≤5。
- 阿普司特可能对较早阶段的较轻中度疾病尤其有益。
核心结论
- 与更严重皮肤病变相比,更中度病变患者中观察到更高的PASI≤2达标率。
- 阿普司特可能在治疗范式早期、更中度疾病中尤其有益。
研究设计与样本
- 汇总分析纳入ESTEEM 1和2、LIBERATE、UNVEIL四项临床试验中随机接受阿普司特30mg每日两次的中重度斑块状银屑病患者。
- 共1062例患者,其中963例ScPGA≥1,643例NAPSI≥1;771例有基线和第32周PASI评估者纳入第32周PASI达标分析。
- 按基线PASI四分位分组:Q1 2.4-13.1;Q2 13.2-15.9;Q3 16.0-20.0;Q4 20.1-57.8。
主要发现
- 第32周PASI≤2达标率在较低PASI四分位更高:Q1 43.5%;Q2 31.2%;Q3 26.8%;Q4 18.4%。
- 达到PASI≤2目标的患者中83.6%在第32周达到DLQI≤5;未达到PASI≤2目标的患者中59.3%达到DLQI≤5。
- 第32周ScPGA和NAPSI平均改善在更中度与更严重疾病间相似(ScPGA范围1.1-1.4;NAPSI范围1.6-2.5)。
- 亚组分析中,最低PASI四分位和病程<5年者PASI≤2达标率更高。
临床怎么用
- 对于中重度斑块状银屑病,基线PASI较低者使用阿普司特更易达到PASI≤2的绝对治疗目标。
- 病程较短(<5年)的患者可能从阿普司特治疗中更多获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)-75 is emerging as an important clinical concept included in psoriasis guidelines and clinical practice. Achieving treatment targets is associated with achievement of long-term outcomes. OBJECTIVE: To evaluate the relationship between psoriasis severity, disease characteristics and achievement of PASI ≤2 with apremilast in a pooled analysis of the phase 3 ESTEEM 1 and 2 (NCT01194219 and NCT01232283), phase 3b LIBERATE (NCT01690299) and phase 4 UNVEIL (NCT02425826) clinical trials. METHODS: Pooled data from patients with moderate-to-severe plaque psoriasis randomized to apremilast 30 mg BID were analysed by baseline PASI quartiles (Q1: 2.4-13.1; Q2: 13.2-15.9; Q3: 16.0-20.0; Q4: 20.1-57.8). Assessments included PASI, Dermatology Life Quality Index (DLQI), Scalp Physician's Global Assessment (ScPGA; ScPGA ≥1) and target (worst) Nail Psoriasis Severity Index (NAPSI; NAPSI ≥1). RESULTS: Of 1062 patients, 963 had ScPGA ≥1 and 643 had NAPSI ≥1; 771 patients with baseline and Week 32 PASI assessments were included in analyses of Week 32 PASI target achievement. Rates of PASI ≤2 at Week 32 were greater in lower PASI quartiles (Q1: 43.5%; Q2: 31.2%; Q3: 26.8%; Q4: 18.4%). Most patients achieving PASI ≤2 target (83.6%) achieved DLQI ≤5 at Week 32; 59.3% of patients who did not achieve PASI ≤2 target achieved DLQI ≤5. At Week 32, mean improvements in ScPGA and NAPSI were similar with more moderate vs. more severe disease (ScPGA, range: 1.1-1.4; NAPSI, range: 1.6-2.5). In a subgroup analysis, achievement of PASI ≤2 target was higher in the lowest PASI quartile and with disease duration <5 years. CONCLUSIONS: Greater achievement of PASI ≤2 was observed in patients with more moderate vs. more severe skin disease. Apremilast may be particularly beneficial in more moderate disease early in the treatment paradigm.
引用
- Reich K, Mrowietz U, Menter A, et al. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. J Eur Acad Dermatol Venereol. 2021. PMID: 34255891. doi:10.1111/jdv.17520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。